J. Goldman & Co LP Takes Position in Celcuity Inc. (NASDAQ:CELC)

J. Goldman & Co LP bought a new position in Celcuity Inc. (NASDAQ:CELC) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 43,345 shares of the company’s stock, valued at approximately $567,000.

Other hedge funds have also added to or reduced their stakes in the company. Barclays PLC boosted its position in Celcuity by 567.6% during the third quarter. Barclays PLC now owns 53,605 shares of the company’s stock valued at $800,000 after buying an additional 45,576 shares during the period. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Celcuity by 97.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 144,032 shares of the company’s stock valued at $1,885,000 after acquiring an additional 71,006 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Celcuity by 83.2% in the 4th quarter. SG Americas Securities LLC now owns 14,646 shares of the company’s stock valued at $192,000 after acquiring an additional 6,651 shares during the last quarter. Bleakley Financial Group LLC purchased a new stake in Celcuity during the 4th quarter valued at about $146,000. Finally, Rhumbline Advisers grew its position in Celcuity by 20.6% during the 4th quarter. Rhumbline Advisers now owns 38,755 shares of the company’s stock worth $507,000 after acquiring an additional 6,625 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Down 3.6%

NASDAQ CELC opened at $10.15 on Monday. Celcuity Inc. has a 1 year low of $7.58 and a 1 year high of $19.77. The stock has a market capitalization of $384.07 million, a PE ratio of -3.89 and a beta of 0.56. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The business’s 50-day moving average is $10.11 and its 200 day moving average is $11.82.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.13). Sell-side analysts forecast that Celcuity Inc. will post -2.62 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on CELC. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research note on Tuesday, April 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Celcuity in a research note on Friday, April 11th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $30.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.